SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

Published 2023 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 41, Issue 17_suppl, Pages LBA4-LBA4
Publisher
American Society of Clinical Oncology (ASCO)
Online
2023-06-07
DOI
10.1200/jco.2023.41.17_suppl.lba4

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.